Management of Nivolumab-Induced Fever

Clinical Presentation and Diagnosis

Nivolumab-induced fever typically presents as an isolated symptom or accompanied by other symptoms indicating potential organ inflammation, and should be considered an important immune-related adverse event (irAE) requiring monitoring, according to the European Society for Medical Oncology 1
Fever may be the first sign of a more serious immune-mediated reaction, and patients should be evaluated for potential concurrent irAEs affecting other organ systems, as recommended by the National Comprehensive Cancer Network 1, 2

The American Society of Clinical Oncology recommends that patients with Grade 1 fever (mild fever <38.5°C) should continue nivolumab therapy with close monitoring, and administer antipyretics such as acetaminophen as needed 2, 1
For Grade 2 fever (moderate fever 38.5-40°C), the European Society for Medical Oncology suggests considering temporarily withholding nivolumab until fever resolves, and administering antipyretics on a scheduled basis, with a strength of evidence rated as high 2, 1
In cases of Grade 3-4 fever (severe fever >40°C or fever with complications), the National Comprehensive Cancer Network recommends immediately withholding nivolumab, initiating high-dose corticosteroids, and considering hospitalization for monitoring and supportive care, with a strength of evidence rated as high 2, 1

The American Academy of Dermatology recommends being vigilant for fever accompanied by specific organ-related symptoms that may indicate serious irAEs, such as respiratory, gastrointestinal, or cutaneous adverse reactions, with a strength of evidence rated as moderate 1, 3
Patients with pre-existing autoimmune conditions may be at higher risk for developing fever and other irAEs, according to the European Society for Medical Oncology, with a strength of evidence rated as low 2

After resolution of fever, the National Comprehensive Cancer Network recommends closely monitoring for recurrence when restarting nivolumab or tapering steroids, with a strength of evidence rated as high 2
The American Society of Clinical Oncology suggests considering prophylactic antibiotics in patients requiring prolonged immunosuppression with corticosteroids, with a strength of evidence rated as moderate 1

The National Comprehensive Cancer Network recommends monitoring for development of other immune-related symptoms, as fever may signal the onset of conditions such as immune-mediated nephritis, thrombocytopenia, or encephalitis, particularly respiratory symptoms that may indicate potential pneumonitis 4

For Grade 2 (Moderate Fever 38.5-40°C), the European Society for Medical Oncology suggests ruling out infection with appropriate cultures and imaging, and monitoring renal function, liver enzymes, and complete blood count to detect early signs of other irAEs 5, 6

The European Society for Medical Oncology recommends documenting the reaction thoroughly to guide management of future nivolumab doses, and notes that the incidence of infusion reactions with PD-1/PD-L1 inhibitors is low (<1% of adverse events in phase III studies), but can increase significantly when combined with other therapies 5, 6

The European Society for Medical Oncology suggests considering premedication with antipyretics for recurrent fever with subsequent nivolumab doses, and evaluating for permanent discontinuation of nivolumab if fever recurs despite premedication, especially if accompanied by other significant irAEs 5, 6
The National Comprehensive Cancer Network recommends considering alternative treatment options in consultation with oncology specialists for patients with a history of severe fever reactions 4

The National Comprehensive Cancer Network recommends educating patients about possible immune-related side effects, including fever, and the importance of promptly reporting symptoms 7
Healthcare providers should be aware of the spectrum of potential immune-mediated adverse events and know how to manage these adverse events, as suggested by the National Comprehensive Cancer Network 7